Remicade is a drug primarily used for reducing the signs and symptoms of Crohn’s disease in patients who have had an inadequate response to conventional therapy, and may also be used to treat plaque psoriasis. It may be used in patients six years of age and older for pediatric Crohn’s disease. Remicade is also used to treat certain types of arthritis and certain bowel diseases. Remicade works by blocking the actions of a natural substance, tumor necrosis factor alpha in the body, which helps to decrease swelling and slow or stop the damage from the disease.
Remicade may cause headache, stomach pain, or nausea. It may also rarely cause potentially fatal liver disease. Some patients have had serious infections caused by viruses, including tuberculosis or histoplasmosis, while unusual cancers have also been reported in teenagers or young children using TNF blocking drugs. The chances of getting lymphoma or other cancers are increased with the use of Remicade.
The FDA has reported 580 adverse reactions among 509,000 worldwide patients. 44 of thee reported a significant blood disorder, and at least 12 patients worldwide taking Remicade have died. Lawsuits have also been filed for tuberculosis infections. Up to 15 million Americans are estimated to have latent tuberculosis infections, which becomes active once the immune system is suppressed, as by Remicade. Lawyers are evaluating research surrounding the potential safety concerns of Remicade, involving cancer and cases of individuals who developed fungal infections.